Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

80.61
-4.3000-5.06%
Post-market: 81.150.5400+0.67%19:54 EDT
Volume:1.41M
Turnover:113.93M
Market Cap:3.93B
PE:-18.65
High:85.17
Open:84.89
Low:79.77
Close:84.91
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.47
T/O Rate:4.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-307.57
PE(LYR):-21.27

Loading ...

Movement Alert|Celcuity Inc Falls 22.15% in Regular Trading, FDA Approval of Core Drug Triggers Classic Sell-the-News Selloff

Market Focus
·
Jul 15

Celcuity Shares Fall 22% as Delayed Launch of New Breast Cancer Drug Overshadows First U.S. Approval

THOMSON REUTERS
·
Jul 15

Movement Alert|Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction

Market Focus
·
Jul 15

Celcuity is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 15

Celcuity, Inc. : H.c. Wainwright Raises Target Price to $155 from $145

THOMSON REUTERS
·
Jul 15

Celcuity price target raised to $177 from $160 at Citizens

TIPRANKS
·
Jul 15

U.S. Research Roundup-equinix, Goldman Sachs, Jpmorgan

Reuters
·
Jul 15

Movement Alert|Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK

Market Focus
·
Jul 15

Stocks to Watch: Pentair, Aehr Test Systems, Celcuity, Schmid Group

Dow Jones
·
Jul 15

Celcuity announces FDA approval of Revtorpyk

TIPRANKS
·
Jul 15

Celcuity Says FDA Approves Revtorpyk for Hr+/her2- Pik3ca Wild-type Metastatic Breast Cancer

Reuters
·
Jul 15

Celcuity Announces FDA Approval of Revtorpyk™ (gedatolisib) for the Treatment of Hr+/her2-, Pik3ca Wild-type Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 15

Celcuity - Anticipates Revtorpyk Commercial Launch in Late Q3 2026

THOMSON REUTERS
·
Jul 15

Movement Alert|Celcuity Inc Falls 6.75% in After-Hours Trading, Trading at $108.9

Market Focus
·
Jul 15

US FDA Approves Celcuity's Breast Cancer Drug

Reuters
·
Jul 15

FDA: Approves Gedatolisib with Fulvestrant, with or Without Palbociclib, for Hr-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 15

Movement Alert|Celcuity Rises 5.22% in Regular Trading, FDA Key Review Date Just Two Days Away Boosting Market Expectations

Market Focus
·
Jul 15

FDA approves Celcuity’s gedatolisib combo for certain breast cancers

TIPRANKS
·
Jul 15

Movement Alert|Celcuity Falls 5.37% in Regular Trading, Heightened Volatility as FDA Review Date Approaches

Market Focus
·
Jul 09

Movement Alert|Celcuity Inc Rises 5.02% in Regular Trading, FDA Review Target Date for Core Drug Just One Week Away

Market Focus
·
Jul 08